Today's Highlights
Premium
FDA Approved Alnylam Pharmaceuticals sNDA for AMVUTTRA® - A Treatment for Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis in Adults to Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations and Urgent Heart Failure Visits
Alnylam Pharmaceuticals in the NEWS March 20, 2025, Alnylam Pharmaceuticals ( ALNY ) - the leading RNAi therapeutics company, today announced that the U.S. FDA has approved the supplemental New Drug...
P
Prohost Biotech
1 min read
1
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion